Early data show an overall survival trend favoring the combination of amivantamab and lazertinib compared to osimertinib; consistent results seen in patients with and without brain metastases1 Late-breaking results from the MARIPOSA study featured in a Presidential Symposium at 2023 ESMO Congress1 BEERSE, BELGIUM, Oct.

早期数据显示，与osimertinib相比，有利于amivantamab和lazertinib联合治疗的总体生存趋势；在有和没有脑转移的患者中观察到的一致结果1 MARIPOSA研究的最新结果在2023年ESMO大会的总统研讨会上得到了特色1比利时比尔森，10月。

23, 2023 (GLOBE NEWSWIRE) -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced results from the Phase 3 MARIPOSA study showing RYBREVANT®▼ (amivantamab) in combination with lazertinib compared to osimertinib resulted in a 30 percent reduction in the risk of disease progression or death (Hazard Ratio [HR]=0.70; 95 percent Confidence Interval [CI], 0.58–0.85; P<0.001) in the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with either epidermal growth factor receptor (EGFR) exon 19 deletions (ex19del) or L858R substitution.1 Results also showed a favourable trend in overall survival (OS) for amivantamab and lazertinib in these patients compared to osimertinib (HR=0.80; 95 percent CI, 0.61–1.05; P=0.11) at a first interim analysis.1 These data were presented in a Presidential Symposium at the European Society for Medical Oncology (ESMO) 2023 Congress taking place 20-24 October in Madrid, Spain (Abstract #LBA14).1 “Despite advances in EGFR-mutated NSCLC treatment, novel targeted therapies and regimens are needed to address resistance and disease progression, which are nearly inevitable with current treatments,” said Byoung Chul Cho*, M.D., Ph.D., medical oncologist and professor in the Division of Medical Oncology at Yonsei Cancer Center, Yonsei University College of Medicine in Seoul, Republic of Korea, and presenting author.

232023（GLOBE NEWSWIRE）-强生的杨森制药公司今天宣布了第3阶段MARIPOSA研究的结果，显示RYBREVANT®▼ （amivantamab）联合lazertinib与osimertinib相比，在局部晚期或转移性非小细胞肺癌（NSCLC）患者的一线治疗中，疾病进展或死亡的风险降低了30%（危险比[HR]0.70；95%置信区间[CI]，0.58-0.85；P 0.001）19个缺失（ex19del）或L858R替代[1]。与osimertinib相比，这些患者的amivantamab和lazertinib的总生存期（OS）也有良好的趋势（HR=0.80；95%CI，0.61-1.05；P=0.11）在第一次中期分析中.1这些数据在20-24日举行的欧洲肿瘤内科学会（ESMO）2023大会总统研讨会上发表10月在西班牙马德里（摘要＃LBA14）.1“尽管EGFR突变NSCLC治疗取得了进展，但仍需要新的靶向治疗和方案来解决耐药性和疾病进展，这在目前的治疗方法中几乎是不可避免的，”Byoung-Chul Cho*博士，医学肿瘤学家和延世癌症中心肿瘤内科教授，延世大学医学院在韩国首尔，并提交作者。

“With the combination of amivantamab and lazertinib.

“与amivantamab和lazertinib的组合。